Drug Profile
Murizatoclax - Amgen
Alternative Names: AMG-397Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Amgen
- Developer Amgen; BeiGene
- Class Antineoplastics; Naphthalenes; Pyrazines; Pyridones; Small molecules; Spiro compounds
- Mechanism of Action MCL1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Haematological-malignancies in China (PO)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in Australia (PO)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in France (PO)